ISPRHIGH SIGNALFINANCIAL10-K

ISPR experienced a severe deterioration in stockholders' equity, declining from $34.5M to just $605K, representing a near-complete erosion of shareholder value.

The 98% collapse in stockholders' equity indicates fundamental financial distress and raises serious questions about the company's capital structure and viability. This dramatic balance sheet deterioration, combined with substantial declines across most asset categories, suggests potential solvency concerns that investors should monitor closely.

Comparing 2025-09-15 vs 2024-09-27View on EDGAR →
FINANCIAL ANALYSIS

ISPR's financial position weakened significantly across virtually all metrics, with stockholders' equity nearly wiped out and major declines in cash, receivables, and total assets. While operating cash flow improved meaningfully and R&D expenses were substantially reduced, these positive developments appear insufficient to offset the severe balance sheet deterioration. The overall picture signals a company in financial distress, potentially undertaking cost-cutting measures while facing fundamental capitalization challenges.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-98.2%
$34.5M→$605K

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
+59.7%
-$18.3M→-$7.4M

Operating cash flow surged 59.7% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-53.4%
$779K→$363K

R&D spending cut 53.4% — could signal cost discipline or concerning reduction in innovation investment.

Capital Expenditure
Cash Flow
-44.1%
$2.0M→$1.1M

Capex reduced 44.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Accounts Receivable
Balance Sheet
-33.6%
$59.7M→$39.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Total Deposits
Balance Sheet
-31%
$34.7M→$23.9M

Deposits declined 31% — significant outflows warrant immediate investigation into funding stability.

Cash & Equivalents
Balance Sheet
-30.6%
$35.1M→$24.4M

Cash declined 30.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Assets
Balance Sheet
-28.9%
$102.6M→$72.9M

Current assets declined 28.9% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
-23.9%
$29.8M→$22.6M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Assets
Balance Sheet
-16.7%
$122.6M→$102.2M

Total assets contracted 16.7% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2025-09-15
PRIOR — 2024-09-27
ADDED
As of September 15, 2025, there were 57,277,874 shares of the registrant s common stock, par value $0.0001 per share (the Common Stock ), outstanding.
All statements contained in this Annual Report and any documents we incorporate by reference, other than statements of historical facts, are forward-looking statements including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth.
These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
The words may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements, although not all forward-looking statements contain these identifying words.
We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results.
+7 more — sign up free →
REMOVED
As of September 26, 2024, there were 56,641,041 shares of the registrant s common stock, par value $0.0001 per share (the Common Stock ), outstanding.
Such statements may include, without limitation, statements with respect to the Company s plans, objectives, projections, expectations and intentions and other statements identified by words such as may, will, could, would, should, believes, expects, anticipates, estimates, intends, plans, potential or similar expressions.
These statements are based upon the current beliefs and expectations of the Company s management and do not constitute guarantees of future performance.
Actual results (including, without limitation, the actual timing for and results of the PMTAs described herein, and other FDA review of the Company s products in development), levels of activity, performance or achievements expressed or implied may differ significantly from those set forth in the forward-looking statements.
We do not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the occurrence of unanticipated events, except as may be required under applicable U.S.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →